The dawn of a new era: targeting the “undruggables” with antibody-based therapeutics
The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …
[HTML][HTML] Superantigen recognition and interactions: functions, mechanisms and applications
AM Deacy, SKE Gan, JP Derrick - Frontiers in Immunology, 2021 - frontiersin.org
Superantigens are unconventional antigens which recognise immune receptors outside
their usual recognition sites eg complementary determining regions (CDRs), to elicit a …
their usual recognition sites eg complementary determining regions (CDRs), to elicit a …
[HTML][HTML] Toward homogenous antibody drug conjugates using enzyme-based conjugation approaches
AF Hussain, A Grimm, W Sheng, C Zhang, M Al-Rawe… - Pharmaceuticals, 2021 - mdpi.com
In the last few decades, antibody-based diagnostic and therapeutic applications have been
well established in medicine and have revolutionized cancer managements by improving …
well established in medicine and have revolutionized cancer managements by improving …
[HTML][HTML] Importance and considerations of antibody engineering in antibody-drug conjugates development from a clinical pharmacologist's perspective
AT Lucas, A Moody, AN Schorzman, WC Zamboni - Antibodies, 2021 - mdpi.com
Antibody-drug conjugates (ADCs) appear to be in a developmental boom, with five FDA
approvals in the last two years and a projected market value of over $4 billion by 2024 …
approvals in the last two years and a projected market value of over $4 billion by 2024 …
Antibody-Drug Conjugates: A promising breakthrough in cancer therapy
S Parit, A Manchare, AD Gholap, P Mundhe… - International Journal of …, 2024 - Elsevier
Antibody-drug conjugates (ADCs) provide effective cancer treatment through the selective
delivery of cytotoxic payloads to the cancer cells. They offer unparalleled precision and …
delivery of cytotoxic payloads to the cancer cells. They offer unparalleled precision and …
[HTML][HTML] Molecular insights of nickel binding to therapeutic antibodies as a possible new antibody superantigen
The binding of nickel by immune proteins can manifest as Type IV contact dermatitis (Ni-
specific T cells mediated) and less frequently as Type I hypersensitivity with both …
specific T cells mediated) and less frequently as Type I hypersensitivity with both …
[HTML][HTML] Peering into avian influenza a (H5N8) for a framework towards pandemic preparedness
2014 marked the first emergence of avian influenza A (H5N8) in Jeonbuk Province, South
Korea, which then quickly spread worldwide. In the midst of the 2020–2021 H5N8 outbreak …
Korea, which then quickly spread worldwide. In the midst of the 2020–2021 H5N8 outbreak …
[HTML][HTML] Recent advances in monoclonal antibody therapy for colorectal cancers
K Hwang, JH Yoon, JH Lee, S Lee - Biomedicines, 2021 - mdpi.com
Colorectal cancer (CRC) is one of the leading causes of cancer deaths worldwide. Recent
advances in recombinant DNA technology have led to the development of numerous …
advances in recombinant DNA technology have led to the development of numerous …
Sagacious epitope selection for vaccines, and both antibody-based therapeutics and diagnostics: tips from virology and oncology
The target of an antibody plays a significant role in the success of antibody-based
therapeutics and diagnostics, and vaccine development. This importance is focused on the …
therapeutics and diagnostics, and vaccine development. This importance is focused on the …
Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis
A Hassanzadeh Eskafi, A Oghalaei… - …, 2023 - Taylor & Francis
Objective Immunotherapy using monoclonal antibodies targeting programmed death ligand-
1 (PD-L1) on cancer cells as a biomarker of escape from response to immune checkpoint …
1 (PD-L1) on cancer cells as a biomarker of escape from response to immune checkpoint …